Altimmune (NASDAQ:ALT) Earns Buy Rating from Analysts at Stifel Nicolaus

Stock analysts at Stifel Nicolaus assumed coverage on shares of Altimmune (NASDAQ:ALT) in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $18.00 price target on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 146.24% from the company’s current price.

Several other brokerages have also recently issued reports on ALT. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Thursday, November 14th. UBS Group started coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.71.

Altimmune Trading Up 0.8 %

ALT stock opened at $7.31 on Wednesday. The firm has a 50 day simple moving average of $8.07 and a 200-day simple moving average of $7.20. The company has a market capitalization of $519.92 million, a P/E ratio of -4.72 and a beta of 0.22. Altimmune has a twelve month low of $5.28 and a twelve month high of $14.84.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the prior year, the business earned ($0.39) earnings per share. On average, research analysts predict that Altimmune will post -1.36 EPS for the current year.

Institutional Investors Weigh In On Altimmune

Several large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its position in shares of Altimmune by 28.6% during the second quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company’s stock worth $1,621,000 after acquiring an additional 54,154 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Altimmune by 190.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,688 shares of the company’s stock worth $98,000 after buying an additional 9,635 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Altimmune in the second quarter worth approximately $70,000. Commonwealth Equity Services LLC lifted its holdings in shares of Altimmune by 9.0% in the second quarter. Commonwealth Equity Services LLC now owns 87,110 shares of the company’s stock valued at $579,000 after buying an additional 7,165 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Altimmune by 25.8% during the 2nd quarter. Rhumbline Advisers now owns 107,446 shares of the company’s stock valued at $715,000 after purchasing an additional 22,034 shares in the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.